Latest Advances in Lung Cancer Research

FDA fast-tracks durvalumab, an immunotherapy drug, for small cell lung cancer. Study shows it may extend patient survival. Decision expected by September 2023. Offers hope for patients.

FDA approves osimertinib for advanced EGFR-mutated NSCLC. This targeted therapy extends progression-free survival in patients who’ve undergone chemoradiation, offering new hope for difficult-to-treat lung cancer.

At WCLC, experts highlighted various side effects of lung cancer treatments, emphasizing thyroid, skin, eye, and lung complications. They stressed the importance of early detection and proactive management for better patient outcomes.

FDA grants Fast Track status to ABD-147, a new lung cancer treatment. This antibody-drug conjugate, developed by AltruBio, could offer hope for ES-SCLC patients with limited options.

China approves Tagrisso combined with chemotherapy as a new first-line treatment option for patients with EGFR-mutated advanced lung cancer.

Japan approves Tagrisso with chemotherapy as a new first-line treatment for EGFR-mutated advanced lung cancer.

Imfinzi shows promise in extending survival for patients with extensive-stage small cell lung cancer.

Lung cancer in never-smokers may respond poorly to immunotherapy due to genetic mutations, suggesting a need for tailored treatments.

Immunotherapy and chemotherapy before surgery show promise for stage 3 NSCLC patients, with 77% achieving two-year progression-free survival.

Dato-DXd shows promise in treating advanced “HER2-low” lung cancer, slowing progression and potentially extending survival.

Stepped palliative care for advanced lung cancer improves quality of life by integrating symptom management and emotional support earlier.

Osimertinib significantly extends progression-free survival in stage III EGFR-mutant lung cancer patients. The drug shows promise as a new standard treatment after chemo and radiation, with manageable side effects.